- Home
- CRBP vs SDHC Comparison
CRBP vs SDHC Comparison
Compare CRBP & SDHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | SDHC |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.6M | 176.7M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | CRBP | SDHC |
|---|---|---|
| Price | $9.69 | $22.09 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $50.29 | $16.70 |
| AVG Volume (30 Days) | ★ 513.0K | 84.9K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $998,173,000.00 |
| Revenue This Year | N/A | $0.47 |
| Revenue Next Year | $100.00 | $7.65 |
| P/E Ratio | ★ N/A | $101.09 |
| Revenue Growth | N/A | ★ 10.26 |
| 52 Week Low | $4.64 | $15.00 |
| 52 Week High | $20.56 | $33.18 |
Technical Indicators
Market Signals| Indicator | CRBP | SDHC |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 69.31 |
| Support Level | $9.44 | $19.72 |
| Resistance Level | $11.64 | $22.41 |
| Average True Range (ATR) | 0.74 | 1.12 |
| MACD | -0.02 | 0.24 |
| Stochastic Oscillator | 12.16 | 92.82 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.